[Comment] Adalimumab in paediatric psoriasis

20:58 EDT 4 May 2017 | The Lancet

Psoriasis is an immune-mediated chronic disease affecting the skin and joints and multiple other organs including the heart.1 Although it affects about 2% of the population worldwide,2 the prevalence of paediatric psoriasis is 0·70%,3 as most patients initially present with the disease in adulthood. There is a paucity of approved systemic therapies for the management of paediatric psoriasis. Systemic treatments include, among others, methotrexate, ciclosporin, acitretin,4 etanercept (a tumour necrosis factor [TNF]-α antagonist approved by the US Food and Drug Administration in November, 2016, to treat moderate to severe psoriasis in children aged 4–17 years), and adalimumab (another TNF-α antagonist approved in 2015 by the European Medicines Agency for the treatment of severe plaque psoriasis in children aged 4 years or older).

Original Article: [Comment] Adalimumab in paediatric psoriasis


More From BioPortfolio on "[Comment] Adalimumab in paediatric psoriasis"

Quick Search

Relevant Topics

Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...